The Neurosurgeon's Evolving Role in the Management of Malignant Gliomas
Release Date: June-18-07
Credit Expiration Date: June-30-08
.
This educational activity is designed to meet the needs of neurosurgeons, neuro-oncologists, radiation oncologists, medical oncologists, and other physicians interested in the treatment of primary gliomas.
CREDIT FOR THIS ACTIVITY IS AVAILABLE FOR PHYSICIANS ONLY.
After a patient is diagnosed with a primary glioma, his or her next appointment is often with a neurosurgeon. Being in the first line of response for a malignant brain tumor makes the neurosurgeon a prominent figure in treatment. However the neurosurgeon’s role in managing these patients does not end when the excision is completed. The surgeon is an ongoing part of a multidisciplinary management team that also includes medical oncologists, neuro-oncologists, radiation oncologists, primary care physicians, and other healthcare providers. This podcast features a dialogue between three leading neurosurgeons regarding current treatment approaches, the role of biomarkers, the importance of translational and clinical research, and the future of glioma treatment.
Matthew G. Ewend, MD
Associate Professor & Chief
Division of Neurosurgery
University of North Carolina at Chapel Hill
Durham, North Carolina
Timothy C. Ryken, MD
Associate Professor
Departments of Neurosurgery & Radiation Oncology
University of Iowa
Iowa City, Iowa
Michael A. Vogelbaum, MD, PhD
Associate Director, Brain Tumor & Neuro-Oncology Center
Associate Director, Neurosurgical Oncology
Director, Center for Translational Therapeutics
Cleveland Clinic Foundation
Cleveland, Ohio
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Dr. Ewend discloses advisory board participation for MGI Pharma, Inc.
Dr. Ryken discloses product consultation and advisory committee service for Medtronic, Inc. He is also on the speakers’ bureau for MGI Pharma, Inc., and Schering-Plough Corporation.
Dr. Vogelbaum discloses product consultation and speakers’ bureau participation for Schering-Plough Corporation.
This educational activity may contain discussion of investigational uses of pharmaceutical agents or surgical devices. Some of these agents/devices may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.
Supported through an educational grant from Schering-Plough.
None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in the audio recording are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.